Article

Ophthalmogenetic testing available from Asper Ophthalmics

Asper Ophthalmics continues to work on the development of new genetic tests for numerous ophthalmologic diseases. Among these are ABCR genetic testing, Usher syndrome testing, Leber congenital amaurosis (LCA) genetic testing, autosomal recessive retinitis pigmentosa (AR-RP) genetic testing, autosomal dominant retinitis pigmentosa (AD-RP) genetic testing, and Bardet Biedl syndrome (BBS) genetic testing.

Asper Ophthalmics continues to work on the development of new genetic tests for numerous ophthalmologic diseases.

Among these are ABCR genetic testing, Usher syndrome testing, Leber congenital amaurosis (LCA) genetic testing, autosomal recessive retinitis pigmentosa (AR-RP) genetic testing, autosomal dominant retinitis pigmentosa (AD-RP) genetic testing, and Bardet Biedl syndrome (BBS) genetic testing.

In addition, the company said it has plans to introduce several new tests this year and update existing tests. New tests will be launched for screening of genetic variations related to Best's disease and congenital stationary night blindness. Both tests will cover approximately 100 mutations. Other testing will be available soon for X-linked retinitis pigmentosa, autosomal dominant optic atrophy, and corneal diseases.

For more information, visit Asper Ophthalmics at Booth 800.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.